undamentalytics Newsletter
Sign in

Crescent Biopharma, Inc. income statement

In fiscal 2025, Crescent Biopharma, Inc. reported revenue of $10.8m, up 108340.0% on the year before, operating income of −$153m (a -1407.5% margin) and net income of −$154m. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2012Dec 20122013Dec 20132014Dec 20142015Dec 20152016Dec 20162020Dec 20202021Dec 20212022Dec 20222023Dec 20232025Dec 2025
Revenue154152001010011
Research and development91220252345472820138
Selling, general and administrative237———————
General and administrative———891717191925
Operating income4−11−11−13−32−52−63−47−39−153
Interest expense—————————2
Income before tax—————————−152
Income tax—————————2
Net income4−11−11−13−32−51−63−47−37−154
Diluted EPS$0.02−$0.59−$0.60−$0.67−$1.50−$1.12−$1.23−$0.89−$0.58—
Diluted shares (average)165m18m18m19m21m46m51m53m63m—
EBITDA4−10−11−13−32−51−63−47−39−153

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: CBIO vs LGVNCBIO vs STTKCBIO vs DARE

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Crescent Biopharma, Inc.'s SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Crescent Biopharma, Inc.